Neuro-Oncology Clinical Advisory Board

The Members of the PKC Neuro-Oncology Clinical Advisory Board are among the most highly respected, globally-renowned practitioners in the field of neuro-oncology. It is the professional dedication of these leaders in their field to the longevity and health of their patients that has motivated these brilliant physicians and researchers to accept special invitations from PKC to contribute their expertise, collective judgment, extensive experience, and commitment to advance the efficacy of treatment modalities by consulting in the development of neuro-oncological medical devices at PKC. They will guide PKC in understanding the end user needs of practitioners and patients in the development of highly advanced technology smart drug delivery systems applied to neuro-oncology that will enhance the quality of life and longevity of patients and advance the field of neuro-oncological treatment.

PKC management extends its gratitude and appreciation to these impressive practitioners who have lent their talents to guiding PKC in its efforts to advance smart drug delivery technology in the field of neuro-oncology.

For more information or to inquire about partnering with PKC, please email us at: info@pharmaco-kinesis.com

	Thomas C. Chen M.D., Ph.D. Chairman		Randy Jensen, M.D., Ph.D.
	Mitchel S. Berger, M.D.		Frederick F. Lang, M.D.
	Jeffrey N. Bruce, M.D.		N. Scott Litofsky, M.D.
	Marc C. Chamberlain, M.D.		Russell Lonser, M.D.
	Lisa M. DeAngelis, M.D.		John H. Sampson, M.D., Ph.D.
	Philip H. Gutin, M.D.		Michael A.Vogelbaum, M.D., Ph.D.